An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
| Status: | No longer available |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 55 - 56 |
| Updated: | 4/17/2018 |
An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study
The primary objective is to provide continued access to PRO 140 to a subject who has
completed participation in PRO140_CD02.
completed participation in PRO140_CD02.
This is an open label, single center study designed to provide continued access to PRO 140 to
a subject who have completed participation in PRO140_CD02 and continue to receive clinical
benefit.
The subject will receive weekly PRO 140 SC injection along with oral ART regimen during the
Treatment Phase. The study treatment (PRO 140 SC injections) will be administered by a
qualified medical professional or self-administered by the subject.
a subject who have completed participation in PRO140_CD02 and continue to receive clinical
benefit.
The subject will receive weekly PRO 140 SC injection along with oral ART regimen during the
Treatment Phase. The study treatment (PRO 140 SC injections) will be administered by a
qualified medical professional or self-administered by the subject.
This study will recruit one treatment-experienced, HIV-1 infected patient with CCR5-tropic
virus, who has participated in PRO 140_CD02 clinical trial and is continuing to derive
clinical benefit from PRO 140 treatment.
We found this trial at
1
site
Click here to add this to my saved trials
